DE1165058T1 - Verwendung von azalid-antibiotika zur behandlung oder vorbeugung okulärer infektionen - Google Patents

Verwendung von azalid-antibiotika zur behandlung oder vorbeugung okulärer infektionen

Info

Publication number
DE1165058T1
DE1165058T1 DE1165058T DE00918382T DE1165058T1 DE 1165058 T1 DE1165058 T1 DE 1165058T1 DE 1165058 T DE1165058 T DE 1165058T DE 00918382 T DE00918382 T DE 00918382T DE 1165058 T1 DE1165058 T1 DE 1165058T1
Authority
DE
Germany
Prior art keywords
treating
ocular infections
preventing ocular
azalide antibiotics
azalide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE1165058T
Other languages
English (en)
Inventor
R Dawson
M Bowman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Inc
Original Assignee
Insite Vision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26961283&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE1165058(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Insite Vision Inc filed Critical Insite Vision Inc
Publication of DE1165058T1 publication Critical patent/DE1165058T1/de
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/02Halogenated hydrocarbons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE1165058T 1999-03-31 2000-03-27 Verwendung von azalid-antibiotika zur behandlung oder vorbeugung okulärer infektionen Pending DE1165058T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28216599A 1999-03-31 1999-03-31
US09/346,923 US6239113B1 (en) 1999-03-31 1999-07-02 Topical treatment or prevention of ocular infections
PCT/US2000/007924 WO2000057866A2 (en) 1999-03-31 2000-03-27 Use of azalide antibiotics for the topical treatment or prevention of ocular infections

Publications (1)

Publication Number Publication Date
DE1165058T1 true DE1165058T1 (de) 2002-10-02

Family

ID=26961283

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60020351T Expired - Lifetime DE60020351T2 (de) 1999-03-31 2000-03-27 Azalid-antibiotika zur topischen behandlung oder vorbeugung okulärer infektionen
DE1165058T Pending DE1165058T1 (de) 1999-03-31 2000-03-27 Verwendung von azalid-antibiotika zur behandlung oder vorbeugung okulärer infektionen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60020351T Expired - Lifetime DE60020351T2 (de) 1999-03-31 2000-03-27 Azalid-antibiotika zur topischen behandlung oder vorbeugung okulärer infektionen

Country Status (15)

Country Link
US (5) US6239113B1 (de)
EP (2) EP1165058B1 (de)
JP (1) JP4904621B2 (de)
KR (1) KR100701721B1 (de)
AT (1) ATE296093T1 (de)
AU (1) AU772228B2 (de)
CA (1) CA2368637C (de)
CY (1) CY1107259T1 (de)
DE (2) DE60020351T2 (de)
DK (1) DK1165058T3 (de)
ES (1) ES2244421T3 (de)
HK (1) HK1041642B (de)
MX (1) MXPA01009718A (de)
PT (1) PT1165058E (de)
WO (1) WO2000057866A2 (de)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6844004B2 (en) * 1997-08-15 2005-01-18 Board Of Regents, The University Of Texas System Topical formulations of natamycin/pimaricin
US6045815A (en) * 1997-08-15 2000-04-04 Board Of Regents, The University Of Texas System Parenteral pimaricin as treatment of systemic infections
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US6685958B2 (en) * 2001-04-25 2004-02-03 Insite Vision Incorporated Quinolone carboxylic acid compositions and related methods of treatment
US6699492B2 (en) * 1999-03-31 2004-03-02 Insite Vision Incorporated Quinolone carboxylic acid compositions and related methods of treatment
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
ES2231275T3 (es) * 1999-10-08 2005-05-16 Affinium Pharmaceuticals, Inc. Inhibidores de fab i.
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
US6914051B1 (en) * 2000-06-28 2005-07-05 David M Allen Penetrating antibiotic gel for soft tissue diseases
WO2002007736A1 (en) * 2000-07-24 2002-01-31 Cadila Pharmaceuticals Limited The process for manufacturing of clear liquid pharmaceutical composition of azithromycin
ATE420640T1 (de) * 2001-04-06 2009-01-15 Affinium Pharm Inc Fab-i-inhibitoren
FR2823441B1 (fr) * 2001-04-12 2004-09-10 Thea Lab Composition pharmaceutique a base de macrolides pour application locale en ophtalmologie et son procede de preparation
KR100431431B1 (ko) * 2001-04-25 2004-05-14 한미약품 주식회사 아지트로마이신 수화물의 1,2-프로필렌글리콜 내포화합물,그의 제조방법 및 그의 약학적 조성물
WO2002092106A1 (en) * 2001-05-11 2002-11-21 Pacific Pharmaceuticals Limited Taste masking pharmaceutical composition
CA2458135A1 (en) * 2001-08-21 2003-03-06 Pfizer Products Inc. Single dose azithromycin for treating respiratory infections
HUP0402291A2 (hu) * 2001-10-18 2005-03-29 Teva Pharmaceutical Industries Ltd. Stabilizált azithromycin összetételek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
US20080149521A9 (en) * 2001-10-18 2008-06-26 Michael Pesachovich Methods of stabilizing azithromycin
WO2003041500A1 (en) * 2001-11-14 2003-05-22 Board Of Regents, The University Of Texas System Topical formulations of natamycin/pimaricin
JPWO2003072589A1 (ja) * 2002-02-26 2005-06-16 明治製菓株式会社 新規15員環アザライド及び新規16員環ジアザライド誘導体とその製造法
CA2479351C (en) * 2002-03-18 2012-05-15 Novartis Ag Topical composition comprising a cyclofructan, a carrier and a drug
US7354574B2 (en) * 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
ES2518316T3 (es) 2002-12-06 2014-11-05 Debiopharm International Sa Compuestos heterocíclicos, métodos de fabricación de los mismos y su uso en terapia
JP4880448B2 (ja) 2003-03-17 2012-02-22 アフィナム ファーマシューティカルズ,インコーポレーテッド 複数の抗生物質を含む組成物、及びそれを用いる方法
US20040202687A1 (en) * 2003-04-14 2004-10-14 Babu M.K. Manoj Ciprofloxacin formulations and methods of making and using the same
US20050085446A1 (en) * 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
US7125497B1 (en) * 2003-05-22 2006-10-24 Sandia Corporation Reactive formulations for a neutralization of toxic industrial chemicals
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7585517B2 (en) * 2003-09-18 2009-09-08 Macusight, Inc. Transscleral delivery
US20050181018A1 (en) * 2003-09-19 2005-08-18 Peyman Gholam A. Ocular drug delivery
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) * 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US20050095205A1 (en) * 2003-10-31 2005-05-05 Ramesh Krishnamoorthy Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
SI1828167T1 (sl) * 2004-06-04 2014-12-31 Debiopharm International Sa Forum "Apres-Demain" Akrilamidni derivati kot anitibiotična sredstva
WO2006004085A1 (ja) 2004-07-02 2006-01-12 Wakamoto Pharmaceutical Co., Ltd. アジスロマイシン含有水性医薬組成物及びその調製方法
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
JP2008526948A (ja) * 2005-01-14 2008-07-24 グラクソスミスクライン・イストラジヴァッキ・センタル・ザグレブ・ドルズバ・ゼー・オメイェノ・オドゴヴォルノスティオ 抗マラリア活性を有する9a−カルバモイルおよびチオカルバモイルアザライド
KR101387456B1 (ko) 2005-02-09 2014-04-21 산텐 세이야꾸 가부시키가이샤 질환 또는 상태의 치료를 위한 액체 제제
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
BRPI0609432A2 (pt) * 2005-03-21 2010-04-06 Macusight Inc sistemas de distribuição de fármacos para tratamento de doenças ou condições
FR2884716B1 (fr) * 2005-04-22 2009-08-21 Thea Sa Lab Utilisation de l'azithromycine pour la fabrication d'un medicament destine au traitement des infections oculaires
CN100393738C (zh) * 2005-07-05 2008-06-11 广州市微生物研究所 纳他霉素的提取纯化方法
US20070014760A1 (en) * 2005-07-18 2007-01-18 Peyman Gholam A Enhanced recovery following ocular surgery
AU2006270041B2 (en) 2005-07-18 2011-08-18 Minu, Llc Enhanced ocular neuroprotection/neurostimulation
US20070048389A1 (en) * 2005-08-26 2007-03-01 Fu-Pao Tsao Stabilized and preserved ketotifen ophthalmic compositions
US20090156578A1 (en) * 2005-12-05 2009-06-18 PAULS Henry 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
RS55632B1 (sr) 2005-12-13 2017-06-30 Incyte Holdings Corp Heteroaril substituisani pirolo[2,3-b]piridini i pirolo[2-3-b]pirimidini kao inhibitori janus kinaze
JPWO2007074904A1 (ja) * 2005-12-28 2009-06-04 わかもと製薬株式会社 水性医薬組成物
US20100130580A1 (en) * 2006-01-25 2010-05-27 Aciex Therapeutics, Inc. Formulations and Methods for Treating Dry Eye
US8492400B2 (en) 2006-02-09 2013-07-23 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
US7767217B2 (en) 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
ES2563288T3 (es) 2006-03-23 2016-03-14 Santen Pharmaceutical Co., Ltd Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
US7758553B2 (en) * 2006-04-03 2010-07-20 Insight Vision Incorporated Drop dispenser for the delivery of uniform droplets of viscous liquids
US20070249546A1 (en) * 2006-04-22 2007-10-25 Sawaya Assad S Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them
CA2654450A1 (en) * 2006-06-05 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted erythromycin analogs
US8318720B2 (en) * 2006-07-20 2012-11-27 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as Fab I inhibitors
WO2008057364A1 (en) * 2006-11-02 2008-05-15 Riolan Technologies, Inc. Method for treating blepharitis
WO2008085913A1 (en) * 2007-01-04 2008-07-17 Rib-X Pharmaceuticals, Inc. Methods for treating, preventing, or reducing the risk of opthalmic, otic, and nasal infections
WO2008098374A1 (en) * 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
CU24179B1 (es) 2007-06-13 2016-04-25 Incyte Corp SALES DE ÁCIDO MALEICO Y DE ÁCIDO SULFÚRICO DE (R)-3-(4-(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)-1H-PIRAZOL-1-IL)-3-CICLOPENTILPROPANITRILO
CA2694403C (en) * 2007-07-25 2013-09-24 Ixodes Gmbh Topical antibiotic composition for the prevention of lyme disease
US7795231B2 (en) * 2007-10-04 2010-09-14 Insite Vision Incorporated Concentrated aqueous azalide formulations
ATE534390T1 (de) * 2007-11-19 2011-12-15 Bausch & Lomb Verwendung von levocabastin zur modulierung der erzeugung von proinflammatorischen zytokinen
EP2098219A1 (de) 2008-03-05 2009-09-09 PARI Pharma GmbH Makrolidzusammensetzungen mit verbessertem Geschmack und verbesserter Stabilität
KR101534422B1 (ko) 2008-05-14 2015-07-09 오토노미, 인코포레이티드 귀 질환 치료를 위한 제어 방출형 코르티코스테로이드 조성물 및 방법
CN102159950B (zh) * 2008-06-13 2014-12-17 凯斯西部预备大学 治疗角膜炎症的组合物和方法
US20100010082A1 (en) * 2008-07-09 2010-01-14 Aspreva International Ltd. Formulations for treating eye disorders
CA2730120A1 (en) 2008-07-10 2010-01-14 Inspire Pharmaceuticals, Inc. Method of treating blepharitis
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
US20100158821A1 (en) * 2008-12-22 2010-06-24 Eastman Chemical Company Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products
EP2393355A4 (de) * 2009-01-23 2012-07-25 Inspire Pharmaceuticals Inc Verfahren zur behandlung von trockenem auge mit azithromycin
US10980818B2 (en) * 2009-03-06 2021-04-20 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
US10201548B2 (en) * 2009-03-06 2019-02-12 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
US20170128481A9 (en) * 2009-03-06 2017-05-11 Insite Vision Corporation Ocular treatment with reduced intraocular pressure
EP2427174A4 (de) * 2009-05-04 2014-01-15 Santen Pharmaceutical Co Ltd Hemmer des mtor-signalwegs zur behandlung von augenleiden
US8106111B2 (en) * 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
CA2762174C (en) * 2009-05-22 2018-02-20 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
JP6172939B2 (ja) * 2009-05-22 2017-08-02 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Jak阻害薬としての3−[4−(7h−ピロロ[2,3−d]ピリミジン−4−イル)−1h−ピラゾール−1−イル]オクタン−またはヘプタン−ニトリル
TW201113285A (en) * 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US20120277199A1 (en) * 2009-10-21 2012-11-01 Otonomy, Inc. Modulation of Gel Temperature of Poloxamer-Containing Formulations
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders
DK3050882T3 (en) 2010-03-10 2018-03-19 Incyte Holdings Corp PIPERIDIN-4-YL-AZETIDINE DERIVATIVES AS JAK1 INHIBITORS
US10045996B2 (en) 2010-03-17 2018-08-14 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
EP2574168B9 (de) 2010-05-21 2016-10-05 Incyte Holdings Corporation Topische formulierung für einen jak-hemmer
EP2444063A1 (de) 2010-10-20 2012-04-25 Novaliq GmbH Flüssige pharmazeutische Zusammensetzungen zur Abgabe von Wirkstoffen
EP2462921A1 (de) 2010-11-11 2012-06-13 Novaliq GmbH Flüssige pharmazeutische Zusammensetzungen zur Behandlung einer Erkrankung der Hinterseite des Auges
MX344478B (es) 2010-11-19 2016-12-16 Incyte Holdings Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de janus cinasas (jak).
CA2818545C (en) 2010-11-19 2019-04-16 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
JP6039145B2 (ja) 2011-05-25 2016-12-07 ノバリック ゲーエムベーハー 半フッ化アルカンを基礎にした局所薬学的組成物
JP6023181B2 (ja) 2011-05-25 2016-11-09 ノバリック ゲーエムベーハー 爪に投与するための医薬組成物
TWI577676B (zh) 2011-06-20 2017-04-11 英塞特控股公司 作為jak抑制劑之吖丁啶基苯基、吡啶基或吡基羧醯胺衍生物
EP2726081A4 (de) * 2011-06-29 2015-04-15 Insite Vision Inc Verfahren zur behandlung einer wiederkehrenden meibomdrüsenerkrankung und verminderung der frequenz von deren wiederauftreten
CN102352058B (zh) * 2011-08-04 2013-04-24 华南农业大学 稳定水溶性纤维素水凝胶粘度的复合添加剂及应用
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為jak抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
WO2013065028A1 (en) * 2011-11-04 2013-05-10 Micro Labs Limited Fixed dose combination containing azithromycin and loteprednol for treatment of ocular infections
PL2806886T3 (pl) 2012-01-23 2017-08-31 Novaliq Gmbh Stabilizowane kompozycje białkowe oparte na semifluorowanych alkanach
WO2013173720A1 (en) 2012-05-18 2013-11-21 Incyte Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
TR201909016T4 (tr) 2012-06-19 2019-07-22 Debiopharm Int Sa (E)-n-metil-n-((3-metilbenzofuran-2-il)metil)-3-(7-okso-5,6,7,8-tetrahidro-1,8-naftiridin-3-il)akrilamidin ön ilaç türevleri.
KR20140009819A (ko) * 2012-07-13 2014-01-23 주식회사유한양행 반코마이신 또는 그의 염 및 덱사메타손 포스페이트 또는 그의 염을 포함하는 국소투여용 약학 조성물
PL2895144T3 (pl) 2012-09-12 2017-07-31 Novaliq Gmbh Kompozycje semifluorowanych alkanów
ES2770398T3 (es) 2012-09-12 2020-07-01 Novaliq Gmbh Composiciones que comprenden mezclas de alcanos semifluorados
CA3178452A1 (en) 2012-11-15 2014-05-22 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
SI3489239T1 (sl) 2013-03-06 2022-04-29 Incyte Holdings Corporation Postopki in intermediati za pripravo zaviralca JAK
CA2900840C (en) * 2013-03-14 2023-03-28 Panoptica, Inc. Ocular formulations for drug-delivery to the posterior segment of the eye
US9044508B2 (en) 2013-03-15 2015-06-02 Insite Vision Corporation Concentrated aqueous azalide formulations
WO2014160579A1 (en) * 2013-03-25 2014-10-02 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
BR112016001522B1 (pt) 2013-07-23 2019-10-01 Novaliq Gmbh Composições de anticorpo estabilizado
RS60469B1 (sr) 2013-08-07 2020-07-31 Incyte Corp Dozni oblici sa produženim oslobađanjem za jak1 inhibitor
US9486405B2 (en) 2013-08-27 2016-11-08 Otonomy, Inc. Methods for the treatment of pediatric otic disorders
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
CA2952772C (en) 2014-06-20 2018-06-12 Erwin C. Si Ophthalmic composition for the treatment of ocular infection
US9241971B1 (en) 2014-07-18 2016-01-26 Kurobe, Llc Topical vancomycin formulation and methods of use
RU2580631C1 (ru) * 2015-03-19 2016-04-10 Общество с ограниченной ответственностью "Научно-внедренческий центр Агроветзащита" Антибактериальное лекарственное средство в форме мази для лечения глазных болезней у животных
WO2017055453A1 (en) 2015-09-30 2017-04-06 Novaliq Gmbh Semifluorinated compounds for ophthalmic administration
JP6602964B2 (ja) 2015-09-30 2019-11-06 ノバリック ゲーエムベーハー 半フッ素化化合物およびその組成物
RU2610408C1 (ru) * 2016-01-11 2017-02-09 Акционерное общество "Екатеринбургский центр МНТК "Микрохирургия глаза" Способ лечения острых бактериальных послеоперационных эндофтальмитов
SI3419628T1 (sl) 2016-02-26 2021-03-31 Debiopharm International Sa Zdravilo za zdravljenje infekcij diabetičnega stopala
CA3027767C (en) 2016-06-23 2024-01-30 Novaliq Gmbh Topical administration method
WO2018035183A1 (en) 2016-08-16 2018-02-22 University Of Rochester Pharmaceutical composition containing polymyxin b/trimethoprim based therapeutics
CN109890374A (zh) 2016-09-22 2019-06-14 诺瓦利克有限责任公司 用于治疗睑缘炎的药物组合物
JP6869336B2 (ja) 2016-09-23 2021-05-12 ノバリック ゲーエムベーハー シクロスポリンを含む眼科用組成物
AU2018216185B2 (en) 2017-02-02 2023-08-03 Mcmaster University Bicarbonate as a potentiator for antimicrobial agents
JP7072582B2 (ja) 2017-04-21 2022-05-20 ノバリック ゲーエムベーハー ヨウ素組成物
CN110650734A (zh) 2017-05-12 2020-01-03 诺瓦利克有限责任公司 治疗与隐形眼镜有关病症的包含半氟化烷烃的药物组合物
JP2020520999A (ja) * 2017-05-17 2020-07-16 ネクストシア インコーポレイテッド 治療有効性を高めるためのリン脂質症の誘発
WO2018215638A1 (en) 2017-05-26 2018-11-29 Novaliq Gmbh Pharmaceutical compositions comprising azithromycin
CA3076776A1 (en) 2017-09-27 2019-04-04 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
WO2019068763A1 (en) 2017-10-04 2019-04-11 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING F6H8
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
WO2019152374A1 (en) 2018-01-30 2019-08-08 Incyte Corporation Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
EP3758676A1 (de) 2018-03-02 2021-01-06 Novaliq GmbH Pharmazeutische zusammensetzungen mit nebivolol
CN112423759A (zh) 2018-03-30 2021-02-26 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
WO2020024060A1 (en) 2018-08-01 2020-02-06 Mcmaster University Methods for inhibiting microbe growth
JP2022502421A (ja) 2018-10-12 2022-01-11 ノバリック ゲーエムベーハー 乾性眼疾患の治療のための眼科用組成物
JP2022529315A (ja) 2019-04-18 2022-06-21 アズーラ オフサルミックス エルティーディー. 眼障害を処置するための化合物および方法
JP2022530322A (ja) 2019-04-18 2022-06-29 アズーラ オフサルミックス エルティーディー. 眼障害を処置するための化合物および方法
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
EP4247367A1 (de) 2020-11-23 2023-09-27 Sight Sciences, Inc. Formulierungen und verfahren zur behandlung von augenleiden
US11459351B1 (en) 2021-04-05 2022-10-04 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43006B (en) 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
ES8601706A1 (es) 1983-05-16 1985-11-16 Merck & Co Inc Una composicion farmaceutica
US4551456A (en) 1983-11-14 1985-11-05 Merck & Co., Inc. Ophthalmic use of norfloxacin and related antibiotics
US4512982A (en) * 1984-04-13 1985-04-23 Pfizer Inc. 9α-Aza-9α-homoerythromycin compounds, pharmaceutical composition and therapeutic method
US4692454A (en) 1986-02-03 1987-09-08 Warner-Lambert Company Opthalmic use of quinolone antibiotics
RO107257B1 (ro) 1987-07-09 1993-10-30 Pfizer Procedeu de obtinere a unui dihidrat de azitromicina, cristalin
KR920003601B1 (ko) 1987-09-03 1992-05-04 유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드 점안 싸이클로스포린(cyclosporin)의 조성물
US5807830A (en) 1987-12-30 1998-09-15 Cytoven J.V. Method for treatment of purulent inflammatory diseases
US5188826A (en) 1988-02-08 1993-02-23 Insite Vision Incorporated Topical ophthalmic suspensions
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
YU45590A (sh) 1990-03-07 1992-07-20 PLIVA FARMACEVTSKA, KEMIJSKA, PREHRAMBENA I KOZMETIČKA INDUSTRIJA s.p.o. Novi kompleksi odnosno helati antibiotika s dvovalentnim i/ili trovalentnim metalima i postupci za njihovo dobijanje
US5124154A (en) 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
SI9011409A (en) 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
US5912331A (en) 1991-03-15 1999-06-15 Merck & Co., Inc. Process for the preparation of 9-deoxo-9(Z)-hydroxyiminoerythromycin A
US5225399A (en) 1991-04-15 1993-07-06 The Children's Hospital Of Philadelphia Antimicrobial amphiphilic peptides
US5239059A (en) 1991-05-10 1993-08-24 The Children's Hospital Of Philadelphia Ion-channel forming peptides
JP2880338B2 (ja) * 1991-10-25 1999-04-05 株式会社森組 圧搾気体による被移送物の圧送方式
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
US5424290A (en) 1992-10-26 1995-06-13 Magainin Pharmaceuticals Inc. Biologically active peptides and uses therefor
US5340572A (en) 1993-02-08 1994-08-23 Insite Vision Incorporated Alkaline ophthalmic suspensions
US5804558A (en) 1993-07-20 1998-09-08 University Of California Protegrins
US5631004A (en) 1993-09-30 1997-05-20 Alcon Laboratories, Inc. Use of sustained release antibiotic compositions in ophthalmic surgical procedures
JPH09503504A (ja) * 1993-10-01 1997-04-08 ザ、プロクター、エンド、ギャンブル、カンパニー 成人歯周炎の治療のためのアジトロマイシンの用途とこの用途のための局所組成物
JPH09508359A (ja) 1994-01-14 1997-08-26 ゾーマ コーポレイション 抗グラム陽性細菌学的方法および物質
US5441939A (en) 1994-03-04 1995-08-15 Pfizer Inc. 3"-desmethoxy derivatives of erythromycin and azithromycin
US5610198A (en) 1994-03-18 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services Anti-mycobacterial compositions and their use for the treatment of tuberculosis and related diseases
HRP940251B1 (en) 1994-04-15 1998-12-31 Stjepan Mutak Process for the preparation of azithromycin dihydrochloride
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
ES2079320B1 (es) * 1994-05-17 1996-10-16 Cusi Lab Disolucion oftalmica a base de un diclofenaco y tobramicina y sus aplicaciones.
US6309630B1 (en) 1994-05-24 2001-10-30 Insite Vision Incorporated Non-steroidal anti-inflammatory ophthalmic suspensions
WO1996019489A1 (en) 1994-12-19 1996-06-27 Russinsky Limited Compounds
US5872104A (en) 1994-12-27 1999-02-16 Oridigm Corporation Combinations and methods for reducing antimicrobial resistance
US5767153A (en) 1995-06-07 1998-06-16 Insite Vision Incorporated Sustained release emulsions
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
EP1525858A1 (de) 1995-06-07 2005-04-27 Durect Corporation Kontrolliertes Zuführsystem mit einer Flüssigkeit von hoher Viskosität
US5888973A (en) 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
GB9621771D0 (en) 1996-10-18 1996-12-11 St George S Enterprises Ltd Method of treatment of heart disease
US5814655A (en) 1996-11-14 1998-09-29 Insite Vision Incorporated Non-steroidal ophthalmic mixtures
PT102006B (pt) 1997-05-19 2000-06-30 Hovione Sociedade Quimica S A Novo processo de preparacao de azitromicina
US6265444B1 (en) 1997-05-23 2001-07-24 Insite Vision Incorporated Ophthalmic composition
US6159458A (en) 1997-11-04 2000-12-12 Insite Vision Sustained release ophthalmic compositions containing water soluble medicaments
US6861411B1 (en) 1997-12-02 2005-03-01 Pfizer, Inc. Method of treating eye infections with azithromycin
DE69825128T3 (de) 1997-12-02 2010-05-06 Pfizer Products Inc., Groton Verwendung von azithromycin zur topischen behandlung von augeninfektionen
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
IT1313610B1 (it) 1999-08-09 2002-09-09 S I F I Societa Ind Farmaceuti Processo per la preparazione di formulazioni acquose per uso oftalmico
WO2003011266A2 (en) 2001-08-01 2003-02-13 Pfizer Products Inc. Azalide antibiotic compositions

Also Published As

Publication number Publication date
ES2244421T3 (es) 2005-12-16
KR20020005634A (ko) 2002-01-17
US20030206956A1 (en) 2003-11-06
EP1165058A2 (de) 2002-01-02
US6239113B1 (en) 2001-05-29
WO2000057866A3 (en) 2001-08-16
ATE296093T1 (de) 2005-06-15
EP1588702A1 (de) 2005-10-26
DK1165058T3 (da) 2005-09-19
JP4904621B2 (ja) 2012-03-28
JP2002540147A (ja) 2002-11-26
US20080161250A1 (en) 2008-07-03
HK1041642B (zh) 2005-12-23
CA2368637A1 (en) 2000-10-05
WO2000057866A2 (en) 2000-10-05
DE60020351T2 (de) 2006-01-26
US7732415B2 (en) 2010-06-08
DE60020351D1 (de) 2005-06-30
US7749970B2 (en) 2010-07-06
HK1041642A1 (en) 2002-07-19
US6569443B1 (en) 2003-05-27
US20040266702A1 (en) 2004-12-30
AU3920300A (en) 2000-10-16
EP1165058B1 (de) 2005-05-25
CY1107259T1 (el) 2012-11-21
AU772228B2 (en) 2004-04-22
CA2368637C (en) 2011-01-18
KR100701721B1 (ko) 2007-03-29
MXPA01009718A (es) 2002-08-12
PT1165058E (pt) 2005-10-31

Similar Documents

Publication Publication Date Title
DE1165058T1 (de) Verwendung von azalid-antibiotika zur behandlung oder vorbeugung okulärer infektionen
DE68917163D1 (de) Antibakterielle Mittel.
DE60307860D1 (de) Aminocyclohexenchinoline und ihre azaisosterischen analoga mit antibakterieller wirkung
BE2011C037I2 (de)
ATE222126T1 (de) Minocyclin und edta enthaltende beschichtungszusammensetzung für medizinische geräte
TR199900733T2 (xx) Patojenik organizmalar ile nasofarinksin kolonizasyonu ile ilgili bakteriyal enfeksiyonlar�n tedavisi i�in bir ilac�n imalat�nda mupirosin kullan�m�.
EA200500804A1 (ru) Топические противоинфекционные композиции
NO934706L (no) Substituerte 4-fenyl-pyridoner og 4-fenyl-2-alkoksypyridiner
PT925789E (pt) Es oculares utilizacao de azitromicina no tratamento topico de infecco
ATE81776T1 (de) Verwendung von chinolon und naphthyridinantibiotika zur herstellung von ophthalmischen arzneimitteln.
PT100914A (pt) Uso de compostos capazes de sofrer uma permuta mista com dissulfureto, com uma ligacao dissulfureto, no tratamento de infeccao por hiv
ES2163186T3 (es) Composicion que comprende mupirocina y clorhexidina.
ATE337002T1 (de) Topische behandlung zur vorbeugung von augeninfektionen
EP0389924A3 (de) Verwendung von Purpuromycin zur Behandlung von Vaginalinfektionen
DK0629403T3 (da) Antibiotisk kombination
PT1232173E (pt) Derivados do acido fusidico
BR9914197A (pt) Processo de tratamento da perda de cabelos com o uso de cetoamidas
PT852497E (pt) Utilizacao de derivados de prostano e a sua combinacao com antibioticos no tratamento de infeccoes bacterianas
BR0007491A (pt) Uso de 3-isoxazolidinonas e ácidos hidroxilâmicospara o tratamento de infecções
UA15363A (uk) Засіб для лікуваhhя відкритих пошкоджеhь
UA67058A (en) Composition for treating periodontitis